- Home
- RBOT vs OTLK Comparison
RBOT vs OTLK Comparison
Compare RBOT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- OTLK
- Stock Information
- Founded
- RBOT 2014
- OTLK 2010
- Country
- RBOT United States
- OTLK United States
- Employees
- RBOT N/A
- OTLK N/A
- Industry
- RBOT Medical Specialities
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RBOT Health Care
- OTLK Health Care
- Exchange
- RBOT Nasdaq
- OTLK Nasdaq
- Market Cap
- RBOT 46.7M
- OTLK 48.3M
- IPO Year
- RBOT N/A
- OTLK 2016
- Fundamental
- Price
- RBOT $7.99
- OTLK $1.71
- Analyst Decision
- RBOT Hold
- OTLK Strong Buy
- Analyst Count
- RBOT 2
- OTLK 5
- Target Price
- RBOT $9.25
- OTLK $9.60
- AVG Volume (30 Days)
- RBOT 9.9K
- OTLK 823.9K
- Earning Date
- RBOT 08-11-2025
- OTLK 08-13-2025
- Dividend Yield
- RBOT N/A
- OTLK N/A
- EPS Growth
- RBOT N/A
- OTLK N/A
- EPS
- RBOT N/A
- OTLK 0.83
- Revenue
- RBOT N/A
- OTLK N/A
- Revenue This Year
- RBOT N/A
- OTLK N/A
- Revenue Next Year
- RBOT N/A
- OTLK $379.84
- P/E Ratio
- RBOT N/A
- OTLK $2.06
- Revenue Growth
- RBOT N/A
- OTLK N/A
- 52 Week Low
- RBOT $4.27
- OTLK $0.87
- 52 Week High
- RBOT $19.00
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- RBOT 51.28
- OTLK 46.49
- Support Level
- RBOT $7.53
- OTLK $1.65
- Resistance Level
- RBOT $8.25
- OTLK $1.97
- Average True Range (ATR)
- RBOT 0.58
- OTLK 0.12
- MACD
- RBOT -0.00
- OTLK -0.03
- Stochastic Oscillator
- RBOT 47.27
- OTLK 10.94
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.